Weil Company, Inc. Editas Medicine, Inc. Transaction History
Weil Company, Inc.
- $239 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding EDIT
# of Institutions
244Shares Held
69.3MCall Options Held
564KPut Options Held
428K-
State Street Corp Boston, MA8.76MShares$40.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.56MShares$39.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.83MShares$36 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.53MShares$25.4 Million1.35% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.61MShares$12 Million0.01% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $316M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...